Cyclerion Therapeutics Inc. Common Stock (CYCN)

About CYCN

Cyclerion Therapeutics, Inc., a biopharmaceutical company, engages in the development of treatments for serious diseases serious diseases with novel sGC stimulators in both the central nervous system (CNS) and the periphery. The company is developing Olinciguat, an orally administered vascular soluble guanylate cyclase (sGC) stimulator, which is in Phase 2 clinical trial to treat cardiovascular diseases; and Pralicig…

Sector

Health Care

Industry

Biotechnology: Pharmaceutical Preparations

Employees

1

Website

www.cyclerion.com/

Fundamentals

1-day range

$3.76$4.27

Market cap

$15.11M

P/E (trailing)

—

P/E (forward)

-2.89

EPS (trailing)

$-1.37

Dividend yield

—

Beta

1.78

Avg. volume

31.1K

Forecasts

1 analyst ratings

Cyclerion Therapeutics Inc. Common Stock Competitors

Chosen by industry and closest market cap.

• CYCN

  Cyclerion Therapeutics Inc. Common Stock

  $3.81

  ▼ 4.51%
  Market cap $15.11MP/E —
  $1.03$8.48
• KALA

  KALA BIO Inc. Common Stock

  $0.6949

  ▼ 14.42%
  Market cap $15.14MP/E —
  $0.5867$1,030
• KTTA

  Pasithea Therapeutics Corp. Common Stock

  $0.5975

  ▲ 7.66%
  Market cap $14.92MP/E —
  $0.281$2.06
• PTN

  Palatin Technologies Inc. Common Stock

  $10.48

  ▼ 0.10%
  Market cap $14.64MP/E 85.09
  $5.61$31
• AEON

  AEON Biopharma Inc. Class A Common Stock

  $0.3095

  ▲ 5.27%
  Market cap $14.41MP/E —
  $0.1772$1.45
• MDCX

  Medicus Pharma Ltd. Common Stock

  $0.258

  ▼ 3.73%
  Market cap $16.60MP/E —
  $0.2425$3.05
• OPTH

  Optimi Health Corp. Common Shares

  $4.93

  ▼ 0.80%
  Market cap $16.61MP/E —
  $0.195$11.4

P/E shows — for peers not currently carrying a live signal of their own.

Latest news

• Cyclerion Therapeutics Announces September 4 Record Date For Contingent Value Rights Distribution To Common And Series A Preferred Holders In Connection With Planned Korsana Biosciences Merger
  benzinga · 8/25/2026
• Cyclerion Therapeutics Announces September 4 Record Date For Contingent Value Rights Distribution To Common And Series A Preferred Holders In Connection With Planned Korsana Biosciences Merger
  Benzinga · 8/25/2026

• Peter M. Hecht · July 16, 2026 · Conversion

  351.0K

Institutional Ownership

March 31, 2026

Total shares held

154.6K

Total value held

$237.7K

Institutional holders

16